Brief: Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review
25/01/2026 23:36
Jan 25 (Reuters) - Eisai Co Ltd 4523.T: FDA ACCEPTS LEQEMBI® IQLIKTM (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER PRIORITY REVIEW Source text: ID:nPn22MRca Further company coverage: [4523.T BIIB.O] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout